Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$23.2MCash on Hand
CF+ Cash Runway
Follow PARK by emailGet an email when PARK reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PARK, unsubscribe in one click. Privacy
📣 What PARK Says Is Next
fourth-quarter · “We continue to monitor patient demand, industry and professional staffing trends that could impact our outlook. We expect to provide our full-year 2027 outlook in connection with the reporting of our fourth-quarter and full-year 2026 results. Conference Call As previously announced, the Company will host a conference call to discuss these results tomorrow morning, Friday, November 13, 2026, at 8:30 a.m.”
Company press release, Nov 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Earnings Corrected its Nov 12 third quarter release only to fix the midpoint percent change in the outlook table; revenue rose 6.0% to $64.9 million and net income was $1.7 million, or $0.27 per diluted share. Full-year revenue outlook is $262.0 to $265.0 million. Form 8-K/A · SEC filing · Press release
Nov 12, 2026 ·
Earnings Reported third quarter 2026 revenue of $64.9 million, up 6.0%, with net income of $1.7 million or $0.27 per diluted share, down from $0.72 a year earlier. Adjusted EBITDA was $5.0 million, and full-year revenue outlook is $262.0 to $265.0 million. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 9, 2026 ·
Deal Park Dental Partners completed its acquisition of the Village Family Dental support organization on November 6, 2026, expanding into North Carolina. The company also amended its credit agreement with U.S. Bank, raising the revolving commitment from $15.0 million to $25.0 million. Earnings are due November 12, 2026. Form 8-K · SEC filing · Press release
Oct 13, 2026 ·
Legal Park Dental Partners disclosed unauthorized network access identified August 28, 2026, with data acquired and patient health information involved. Four putative class actions in Minnesota state court are pending, with no material financial impact identified so far. Form 8-K · SEC filing
Sep 1, 2026 ·
Legal Park Dental Partners reported unauthorized access to its computer network identified on August 28, 2026. It is investigating the scope, including possible access to patient data, and says operations are not materially disrupted and no material financial impact has been identified so far. Form 8-K · SEC filing
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 12, 2026 ·
Earnings Park Dental reported Q2 2026 revenue up 5.1% to $66.2 million, but gross margin fell 20.1% to $9.5 million and net income dropped to $1.3 million ($0.22 per diluted share). Adjusted EBITDA was $7.4 million. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
PARK holds $23.2M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Share count 5,535,029 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full PARK picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PARK and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.